AMGN•benzinga•
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Summary
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 14, 2025 by benzinga